Pronostic factors of synchronous brain metastases from lung cancer

Penel, Nicolas; Brichet, A; Prevost, B.; Duhamel, Alain; Assaker, R.; Dubois, François; Lafitte, Jean-Jacques

doi:10.1016/s0169-5002(01)00202-1

Cited by 59 publications

(44 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Historically, the survival of patients with brain metastases has been considered very poor 6,10 , with the risk of death and significant impairments in quality of life being increased by a factor of 4 [11][12][13] . The median survival of patients with untreated brain metastases is reported to be 1-3 months 7,10,11 .…”

Section: Introductionmentioning

confidence: 99%

“…The median survival of patients with untreated brain metastases is reported to be 1-3 months 7,10,11 . The combination of whole-brain radiation (wbrt) and corticosteroids, which has been the standard treatment to palliate symptoms, may result in modest improvements in survival for patients well enough to receive this treatment [14][15][16] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases

et al. 2013

View full text Add to dashboard Cite

Background: The prognosis of patients with brain metastases from non-small-cell lung cancer (NSCLC) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced NSCLC without brain metastases. Methods: In a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness. Results: During the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months). Conclusions: Our data show limited survival in patients with brain metastases from NSCLC. Careful patient selection for more aggressive treatment approaches is necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…It was shown that there is a strong correlation between the primary tumor localization, TNM stage and metastases 20 . A study which investigated the brain metastases in NSCLC patients showed the predicted probability of metastatic disease to the brain was positively correlated with size of the primary tumor, cell type and lymph node stage but did not correlate with primary tumor location 21 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Lung Cancer Patients with Distant Organ Metastasis

Acar¹,

Ünsal²,

Altıntaş³

2016

Kafkas J Med Sci

View full text Add to dashboard Cite

“…24 For patients with favorable prognostic features [good performance status, younger age (<65 years), well-controlled status of the primary lung cancer, and absence of extra-cranial metastasis 6,[25][26][27] ], treatment with SRS and WBRT could prolong OS to 11.6 months. 28 Using RPA as a prognostic factor, meta-analyses by the Radiation Therapy Oncology Group trials on brain metastasis treated with SRS showed that the median survival of the best prognosis group (RPA class I: age <65 years, KPS ≥70, and a controlled systemic disease) was 7.1 months.…”

mentioning

confidence: 99%